Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110&#x03B1; inhibition

Asneha Iqbal; Frank Eckerdt; Jonathan Bell; Ichiro Nakano; Francis J. Giles; Shi-Yuan Cheng; Rishi R. Lulla; Stewart Goldman; Leonidas C. Platanias

doi:10.18632/oncotarget.8899

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition

Asneha Iqbal _, Frank Eckerdt, Jonathan Bell, Ichiro Nakano, Francis J. Giles, Shi-Yuan Cheng, Rishi R. Lulla, Stewart Goldman and Leonidas C. Platanias

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:33192-33201. https://doi.org/10.18632/oncotarget.8899

Metrics: PDF 2327 views | HTML 2461 views | ?

Abstract

Asneha Iqbal1,2, Frank Eckerdt1, Jonathan Bell1,3, Ichiro Nakano4, Francis J. Giles1,3, Shi-Yuan Cheng1, Rishi R. Lulla1,2, Stewart Goldman1,2, Leonidas C. Platanias1,3,5

1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

2Division of Hematology/Oncology/Stem Cell Transplantation, Ann and Robert H. Lurie Children’s Hospital of Chicago, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

3Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

4Department of Neurological Surgery and James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

5Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL, USA

Correspondence to:

Leonidas C. Platanias, e-mail: [email protected]

Keywords: glioblastoma, PIM kinase, mTOR signaling, p110α

Received: February 04, 2016 Accepted: April 05, 2016 Published: April 21, 2016

ABSTRACT

The PIM family of proteins encodes serine/threonine kinases with important roles in protein synthesis and cancer cell metabolism. In glioblastoma (GBM) cell lines, siRNA-mediated knockdown of PIM kinases or pharmacological inhibition of PIM kinases by SGI-1776 or AZD-1208 results in reduced phosphorylation of classic PIM effectors and also elements of the PI3K/mTOR pathway, suggesting interplay between PIM and mTOR signals in GBM cells. Combination of PIM kinase inhibitors with BYL-719, an inhibitor specific for the PI3K catalytic isoform p110α, results in enhanced antineoplastic effects in GBM cells. Additionally, pharmacologic inhibition of PIM kinases impairs growth of patient-derived glioma sphere cells, suggesting an important role for PIM kinases in cancer stem cell (CSC) function and survival. Such effects are further enhanced by concomitant inhibition of PIM kinase and p110α activities. Altogether these findings suggest that pharmacological PIM targeting in combination with PI3K inhibition may provide a unique therapeutic approach for the treatment of heterogeneous tumors containing populations of therapy-resistant CSCs in GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8899

Publication Alerts

Research Papers:

Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition

Abstract